ScoreComparison
Why is Verrica Pharmaceuticals, Inc. ?
1
With a growth in Net Sales of 46.06%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 4 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -14.22 MM
- NET PROFIT(HY) Higher at USD -17.98 MM
- INVENTORY TURNOVER RATIO(HY) Highest at 1.76 times
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -2.73%, its profits have risen by 74%
3
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -1.13% over the previous quarter and currently hold 1.37% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
4
Below par performance in long term as well as near term
- Along with generating -2.73% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Verrica Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Verrica Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Verrica Pharmaceuticals, Inc.
-3.56%
-0.04
858.62%
S&P 500
25.41%
1.92
13.25%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
105.42%
EBIT Growth (5y)
11.23%
EBIT to Interest (avg)
-10.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.63
Sales to Capital Employed (avg)
0.60
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
38.18%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.04
EV to EBIT
-3.84
EV to EBITDA
-4.11
EV to Capital Employed
-9.85
EV to Sales
1.29
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-76.79%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend18What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -14.22 MM
NET PROFIT(HY)
Higher at USD -17.98 MM
INVENTORY TURNOVER RATIO(HY)
Highest at 1.76 times
NET SALES(Q)
At USD 5.02 MM has Grown at 46.06%
-3What is not working for the Company
RAW MATERIAL COST(Y)
Grown by 5.78% (YoY
CASH AND EQV(HY)
Lowest at USD 50.75 MM
OPERATING PROFIT(Q)
Lowest at USD -9.52 MM
Here's what is working for Verrica Pharmaceuticals, Inc.
Net Profit
Higher at USD -17.98 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Operating Cash Flow
Highest at USD -14.22 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
At USD 5.02 MM has Grown at 46.06%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Inventory Turnover Ratio
Highest at 1.76 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Here's what is not working for Verrica Pharmaceuticals, Inc.
Operating Profit
Lowest at USD -9.52 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (USD MM)
Cash and Eqv
Lowest at USD 50.75 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Raw Material Cost
Grown by 5.78% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
